Therefore, better AR inhibitors with {TAIL ~ more potent antagonistic activities} and {HEAD ~ minimal agonistic activities} are needed to delay disease progression and to treat the fatal hormone refractory prostate cancer 
Therefore , better AR inhibitors with { TAIL ~ more potent antagonistic activities } and { HEAD ~ minimal agonistic activities } are needed to delay disease progression and to treat the fatal hormone refractory prostate cancer
OTH OTH OTH OTH OTH OTH TAIL TAIL TAIL TAIL TAIL TAIL TAIL TAIL OTH HEAD HEAD HEAD HEAD HEAD HEAD HEAD OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH